Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total

Not Applicable (1)

P 1 (2)

P 2 (1)

Trial Status

Completed2

Recruiting1

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT07635173Phase 1Completed

SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas

NCT06773481Phase 1Recruiting

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

NCT02795364Not ApplicableUnknown

Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas

NCT01663012Phase 2Completed

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Showing all 4 trials

Glioblastomas (GBM)